Quick Answer
NIKA PHARMACEUTICALS, INC reported Cash and Equivalents of $1.9 thousand for fiscal year 2025.
NIKA PHARMACEUTICALS, INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.9K | -9.3% |
| 2024 | $2.1K | -89.4% |
| 2023 | $19.6K | +2168.1% |
| 2022 | $864.00 | +116.5% |
| 2021 | $399.00 | -75.2% |
| 2020 | $1.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.3K | +353.6% | -59.7% |
| June 30, 2025 | $15.6K | +108.6% | -18.4% |
| March 31, 2025 | $19.1K | -21.8% | +818.7% |
| December 31, 2024 | $2.1K | -89.4% | +50.3% |
| September 30, 2024 | $1.4K | -87.3% | -81.5% |
| June 30, 2024 | $7.5K | -32.3% | -69.4% |
| March 31, 2024 | $24.5K | +448.7% | +24.9% |
| December 31, 2023 | $19.6K | +2168.1% | +79.6% |
- NIKA PHARMACEUTICALS, INC showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, NIKA PHARMACEUTICALS, INC’s cash and equivalents has grown by 17.3% (from $1.6 thousand to $1.9 thousand).
- The most recent figure is from NIKA PHARMACEUTICALS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: